| | 公告日期 无 | 2024-10-30 | 异常期间 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 芭薇股份(837023) 连续竞价 | | 成交数量 （股） | 12341445.0 | 成交金额（万 元） | 20149.83 | | | 当日收盘价涨幅达到20%的前5只股票 涉及事项 | | | | | | | 买/卖 | 营业部或交易单元名称 | | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东莞证券股份有限公司南京分公司 | | | | 4980043.03 | 0 | | 买2 | 广发证券股份有限公司广州天河路营业部 | | | | 4053400 | 0 | | 买3 | 中信证券股份有限公司北京万柳证券营业部 | | | | 3481086.96 | 0 | | 买4 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | | 3134962.24 | 246509.57 | | 买5 | 国泰君安证券股份有限公司广西南宁民族大道营业部 | | | | 2640929.24 | 0 | ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | 832000 | 安徽凤凰 | 24126536.0 | 40469.66 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到67.61% | | 2024-10- | 870204 | 沪江材料 | 31729667.0 | 67880.87 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到67.55% | | 2024-10- | 873223 | 荣亿精密 | 42594651.0 | 47270.81 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到67.50% | | 2024-10- | 836717 | 瑞星股份 | 28931459.0 | 29537.95 | 异常期间涨跌幅偏离值累计 | | 30 | | | | | 达到47.50% | | 2024-10- | 837212 | 智新电子 | 25924840.0 | 45333.71 | ...

第四届监事会第二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 证券代码：837023 证券简称：芭薇股份 公告编号：2024-109 广东芭薇生物科技股份有限公司 二、议案审议情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 29 日 2.会议召开地点：芭薇股份创新中心 8 楼会议室 3.会议召开方式：现场召开 4.发出监事会会议通知的时间和方式：2024 年 10 月 18 日 以电话方式发出 5.会议主持人：监事会主席陈清云先生 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》等法律法规和《公司章程》的相关规 定，所作决议合法合规。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 （一）审议通过《关于公司 2024 年三季度报告》议案 1.议案内容： 具体内容详见公司于 2024 年 10 月 29 日在北京证券交易所信息披露平 台 （www.bse.cn）上披露的《2024 年三季度报告 ...

Financial Performance - Operating revenue for the first nine months of 2024 reached ¥471,201,911.76, a 49.50% increase year-on-year[4] - Revenue for Q3 2024 was ¥205,066,659.35, representing a 101.09% increase compared to Q3 2023[4] - Net profit attributable to shareholders for Q3 2024 increased by 57.52% to ¥14,311,195.11[4] - The company reported a basic earnings per share of ¥0.34 for the first nine months, down 15.81% from the previous year[4] - Total revenue for the first nine months of 2024 reached ¥471,201,911.76, a significant increase from ¥315,175,735.49 in the same period of 2023, representing a growth of approximately 49.5%[24] - Net profit for the first nine months of 2024 was ¥28,764,558.92, compared to ¥30,329,206.28 in 2023, reflecting a decrease of approximately 5.2%[25] - The net profit for the first nine months of 2024 was ¥28,048,676.41, compared to ¥30,136,952.95 in the same period of 2023, indicating a decrease of about 6.9%[26] - The company's total comprehensive income for the first nine months of 2024 was ¥28,022,688.49, down from ¥30,173,428.13 in the same period of 2023, indicating a decrease of approximately 7.1%[27] Cash Flow - Cash flow from operating activities showed a significant decline of 335.58%, resulting in a net outflow of ¥66,266,923.81[4] - The net cash flow from operating activities was -¥66,266,923.81, a decrease of 336% year-over-year, primarily due to an increase in accounts receivable by ¥87.62 million[9] - The net cash flow from operating activities for the first nine months of 2024 was -48,323,658.98, compared to 28,976,060.03 in the same period of 2023, indicating a significant decline[30] - Cash inflow from operating activities totaled ¥443,007,335.59 for the first nine months of 2024, compared to ¥357,853,571.36 in the same period of 2023, representing an increase of about 23.7%[28] - Cash outflow from operating activities increased to ¥484,666,499.86, compared to ¥323,197,323.59 in the prior year, representing a rise of about 50%[30] - The net cash flow from investing activities improved to ¥47,208,971.79, compared to -28,859,797.06 in the same period last year, showing a positive turnaround[30] - Total cash inflow from financing activities was ¥58,084,000.00, compared to ¥15,000,000.00 in the previous year, marking a substantial increase[30] Assets and Liabilities - Total assets increased by 19.51% to ¥792,538,874.54 compared to the end of last year[4] - Total assets increased to CNY 792.54 million as of September 30, 2024, up from CNY 663.18 million on December 31, 2023, representing a growth of approximately 19.5%[20] - Total liabilities increased to CNY 406.47 million from CNY 332.99 million, reflecting a growth of about 22.0%[20] - Total liabilities rose to ¥315,422,499.12, up from ¥274,676,664.07, which is an increase of approximately 14.8%[23] - Shareholders' equity rose to CNY 386.07 million, up from CNY 330.19 million, indicating an increase of approximately 16.9%[20] - The company's equity increased to ¥370,655,485.39 from ¥315,678,571.20, representing a growth of about 17.4%[23] Accounts Receivable and Inventory - Accounts receivable rose by 149% to ¥146,513,980.31, driven by a significant increase in sales[6] - Inventory increased by 93% to ¥99,576,842.05, reflecting higher raw material and finished goods levels due to revenue growth[7] Borrowings and Financial Position - Short-term borrowings surged by 169% to ¥26,964,890.16, indicating increased working capital needs[7] - Long-term borrowings increased to CNY 130.94 million from CNY 105.24 million, representing a growth of about 24.5%[20] - The company reported a decrease in intangible assets to CNY 33.72 million from CNY 35.12 million, a decline of approximately 4.0%[19] Expenses - Operating costs increased to ¥345,549,791.88, reflecting a 67% rise year-over-year, with an increase of ¥139 million[8] - Sales expenses rose to ¥34,110,431.28, a 51% increase from the previous year, with advertising expenses contributing an additional ¥9.39 million[8] - Research and development expenses for the first nine months of 2024 were ¥20,687,231.09, compared to ¥17,868,752.96 in 2023, an increase of approximately 15.5%[24] - The company's financial expenses decreased to ¥2,375,776.79 in the first nine months of 2024, compared to ¥2,987,635.36 in the same period of 2023, reflecting a reduction of about 20.5%[26] - The company reported a decrease in credit impairment losses to ¥-2,736,978.63 from ¥-309,146.78, indicating improved asset quality[25] Shareholder Information - The total number of ordinary shares at the end of the period was 85,800,000, with 32,666,410 shares being freely tradable[11] - The total shareholding of the top ten shareholders accounts for 72.45%, with a total of 62,157,000 shares held[13] - The company has no pledged or judicially frozen shares among the top ten shareholders[14] Future Outlook - Future outlook includes continued focus on market expansion and potential new product development, although specific figures were not disclosed in the call[24] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[26]

证券代码：837023 证券简称：芭薇股份 公告编号：2024-107 广东芭薇生物科技股份有限公司 简式权益变动报告书 信息披露义务人及其主要负责人保证公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 信息披露义务人保证除本报告书披露的信息外，没有通过任何其他方式增加或减 少其在上市公司中拥有权益的股份。 通讯地址：深圳市南山区粤海街道高新区社区高新南四道 88 号光启未来中心 A 座 45A 层 权益变动性质：股份减少 信息披露义务人 2：深圳南海成长同赢股权投资基金(有限合伙) 执行事务合伙人：深圳同创锦绣资产管理有限公司 住所：深圳市南山区粤海街道深南大道 10128 号南山软件园东塔楼 805 室 通讯地址：深圳市南山区粤海街道高新区社区高新南四道 88 号光启未来中心 A 座 45A 层 权益变动性质：股份减少 信息披露义务人 1：杭州叩问股权投资合伙企业(有限合伙) 执行事务合伙人：杭州同创伟业资产管理有限公司 住所：浙江省杭州市余杭区仓前街道景兴路 999 号 2 号楼 320 室 第一节 释义 本报告书中，除非文意载明，下列简称具有以下含义： | 上市公司、公司、 | ...

华创证券有限责任公司 关于退出为广东芭薇生物科技股份有限公司股票 提供做市报价服务的公告 经全国中小企业股份转让系统有限公司同意,自201年|2月20日起,我司将 退出为广东芭薇生物科技股份有限公司股票(证券简称:芭薇股份,证券代码: 837023）提供做市报价服务。 特此公告。 ...

证券代码：837023 证券简称：芭薇股份 公告编号：2024-106 广东芭薇生物科技股份有限公司 三、本次募集资金专项账户注销情况 鉴 于 公 司 用 于 补 充 流 动 资 金 项 目 的 募 集 资 金 账 户 （ 银 行 账 号 ： 44050111716700000792）已按计划使用完毕，为方便募集资金账户管理、降低管理 成本，公司将该项目剩余募集资金 165.71 元（结息）转入公司基本户，用于补充日 常经营流动资金，并申请办理注销该募集资金专项账户。 一、募集资金基本情况 2024 年 2 月 22 日，中国证券监督管理委员会做出《关于同意广东芭薇生物科 技股份有限公司向不特定合格投资者公开发行股票注册的批复》（证监许可〔2024〕 322 号），同意公司向不特定合格投资者公开发行股票的注册申请，公司于 2024 年 3 月 29 日上市。 公司向不特定合格投资者公开发行人民币普通股 9,200,000 股，每股面值为人民 币 1.00 元，每股发行价格为人民币 5.77 元，共募集资金总额为人民币 53,084,000.00 元，扣除发行费用 11,362,992.01 元（不含税），募集 ...

Group 1: Investor Relations Activity Overview - The investor relations activity was held on September 12, 2024, via a network platform, focusing on enhancing investor communication [2] - Participants included the company's chairman, general manager, board secretary, and financial director [2] Group 2: Company Development and Brand Promotion - The company aims to capitalize on the expanding cosmetics market, particularly in emerging markets, by enhancing its core competitiveness and expanding production capacity [3] - The promotion of the company's own brand is supported by strong R&D, testing, and delivery capabilities, with a focus on foreign trade [3] Group 3: Financial Performance and Response to Challenges - In the first half of 2024, the company achieved a revenue of ¥266,135,252.41, representing a year-on-year increase of 24.83% [4] - The net profit for the same period was ¥14,458,026.23, reflecting a decline of 32.62% compared to the previous year [4] - The company plans to adjust its business strategies, increase R&D investment, optimize talent structure, control costs, and enhance market promotion to mitigate performance fluctuations [4]

证券代码：837023 证券简称：芭薇股份 公告编号：2024-104 广东芭薇生物科技股份有限公司 关于参加广东辖区 2024 年投资者网上集体接待日 说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 三、 参加人员 为进一步加强与投资者的互动交流，广东芭薇生物科技股份有限公司（以 下简称"公司"）将参加由广东证监局和广东上市公司协会联合举办的"坚定 信心 携手共进 助力上市公司提升投资价值——2024 广东辖区上市公司投资 者关系管理月活动投资者集体接待日"。 届时公司董事、高管将在线就 2024 年半年度业绩、公司治理、发展战略、 经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎 广大投资者踊跃参与！ 二、 说明会召开的时间、地点 （一）会议召开时间：2024 年 9 月 12 日 15:30-16:30。 （二）会议召开地点 本次投资者网上集体接待日活动将采用网络方式举行，投资者可登录"全 景路演"网站（http://rs.p5w.net）参与 ...

第二条 公司系依照《公司法》和其他有关法律法规的规定成立的股份有 限公司。 广东芭薇生物科技股份有限公司 章程 第一章 总则 第一条 为维护广东芭薇生物科技股份有限公司（以下简称"公司"或"本 公司 "）、公司股东和债权人的合法权益，规范公司的组织和行为，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》 "）、《上市公司章程指引（2023 年修订）》（以下 简称"《章程指引》"）《北京证券交易所股票上市规则（试行）》（以下简称 "《上市规则》"）的规定，制订本章程。 公司由原广州芭薇化妆品有限公司变更设立的股份有限公司；在广州市市场 监督管理局注册登记，统一社会信用代码为 91440101786096533H。 公司经北京证券交易所（以下简称"北交所"）审核并于 2024 年 2 月 22 日经中国证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定， 向不特定合格投资者发行人民币普通股 920.00 万股，于 2024 年 3 月 29 日 在北京证券交易所上市。 第三条 公司具有独立的法人资格，依法享有民事权利和承担民事责任。 第四条 公 ...